OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 13D and 13G filings for Protalix BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-02-16 10:03 am Purchase |
2020-12-31 | 13G | Protalix BioTherapeutics, Inc. PLX |
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,091,176 3.200% |
150,000 (+15.94%) |
Filing |